The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 ...

A nationwide team led by researchers at Baylor College of Medicine, Texas Children’s Hospital and UPMC Children's Hospital of ...

The American Society of Hematology (ASH) and nearly 100 other organizations blasted the dismantling of CDC's Division of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved fitusiran (Qfitlia, Sanofi) for routine prophylaxis for prevention or reduction in bleeding ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

creating potentially life-threatening risks from otherwise normal situations experienced by those without hemophilia. The ...

FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia By Lori Solomon HealthDay Reporter WEDNESDAY, April 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to ...